Shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) have been assigned an average recommendation of "Reduce" from the fifteen brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy recommendation to the

DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) has received a consensus recommendation of "Reduce" from the fifteen analysts that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy recommendation to the company. The

CHARLOTTE, N.C., Dec. 15, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share.

Brandes Investment Partners LP grew its holdings in shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 257.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 376,662 shares of the medical instruments supplier's stock after acquiring an additional 271,221

Shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY - Get Free Report) have been assigned an average rating of "Hold" from the fourteen ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and two have given a buy

Creative Planning grew its stake in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 311.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 113,875 shares of the medical instruments supplier's stock after purchasing an additional 86,227 shares during the period. Creative

Bristol Myers Squibb has a high dividend yield, is very cheap, and may have better growth prospects than it might seem at first glance. Pfizer now has a 7% yield, and may have found a solution to its patent cliff issue.

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:

Bank of Montreal Can grew its position in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 8.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 352,524 shares of the medical instruments supplier's stock after purchasing an additional 26,610 shares during the

Brickwood added 1,496,935 shares of XRAY, raising position value by $19.03 million. The transaction represented 15.2% of Brickwood's 13F reportable assets under management.